CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone
Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the FDA
Read more at prnewswire.comCitius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
